Concert Pharmaceuticals Inc. (NASDAQ:CNCE)’s share price fell 4.3% during mid-day trading on Friday . The company traded as low as $10.11 and last traded at $10.17, with a volume of 70,511 shares changing hands. The stock had previously closed at $10.63.

A number of brokerages have issued reports on CNCE. Brean Capital reaffirmed a “buy” rating on shares of Concert Pharmaceuticals in a research report on Saturday, April 30th. Zacks Investment Research raised Concert Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, Stifel Nicolaus began coverage on Concert Pharmaceuticals in a research report on Friday, July 1st. They issued a “buy” rating and a $23.00 target price on the stock. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. Concert Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $26.43.

The stock’s market cap is $225.38 million. The stock has a 50-day moving average of $11.44 and a 200 day moving average of $12.52.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.03. On average, equities analysts predict that Concert Pharmaceuticals Inc. will post ($2.51) EPS for the current fiscal year.

A hedge fund recently raised its stake in Concert Pharmaceuticals stock. Dimensional Fund Advisors LP boosted its stake in shares of Concert Pharmaceuticals Inc. (NASDAQ:CNCE) by 405.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 224,348 shares of the company’s stock after buying an additional 179,998 shares during the period. Dimensional Fund Advisors LP owned about 1.02% of Concert Pharmaceuticals worth $4,256,000 at the end of the most recent quarter.

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.